| Purpose:To alleviate the clinical symptoms, decrease toxic and side-effects after chemotherapy and improve quality of life in NSCLC patients receiving Fuzheng Peiyuan Electuary therapy combine with chemotherapy, and to observe the effect and the characteristics of reducing bone marrow depression after chemotherapy, preliminarily determine its safety and immunity.Method:The randomized, positive drug control trial was performed in Guang’anmen Hospital, China Academy of Chinese Medical Sciences. Between January2011and March2012,62patients with a histologically confirmed diagnosis of NSCLC and reach the deficiency of both qi and blood standard were enrolled. There into,32patients are in test group (group A), receive Fuzheng Peiyuan Electuary therapy,6g po tid, combining with chemotherapy,30patients are in control group (group B), receive Jianpi Yishen Electuary therapy, lOg po tid, combining with chemotherapy. All patients use receive Fuzheng Peiyuan Electuary or Jianpi Yishen Electuary3weeks. The primary effect observation indexes are blood analysis, Karnofsky performance status (KPS), weight change, score of QOL and symptom improvement, lmmunohistochemistry, safety index are hepatic and renal function, blood glucose, vital signs, ect.Result:1.No statistical significance for the basic conditions of the2groups.2.Comparison of blood routine test:comparing the bone marrow suppression concerning the number of patients who have the decline of white blood cell in2groups, group A is fewer (p>0.05).3.KPS and weight on the QOL:both, in two groups, are improved, but without statistical significance between group A&group B (P>0.05).4.Improvement on the symptoms:the test group has an effective rate in total of90.63%(excellent3cases: effective26cases:invalid3cases) versus the other90%(excellent2cases; effective25cases; invalid3cases)(P>0.05).Conclusion:Fuzheng Peiyuan Electuary can reduce bone marrow depression, alleviate the clinical symptoms and improve quality of life. |
PDF Full Text Request